ALSにおけるIL-2治療の分層化:バイオマーカーの統合 - 著者の回答
Gilbert Bensimon1, P Nigel Leigh2, Timothy Tree3
1Department of Clinical Pharmacology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris 75013, France; Department of Pharmacology, Paris Sorbonne University, Paris, France; Department of Biostatistics, Clinical Epidemiology, Public Health, and Innovation in Methodology, Nîmes University Hospital, Nîmes, France.
Lancet (London, England)
|November 1, 2025
まとめ
No abstract available in PubMed .
さらに関連する動画
09:31Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
Published on: October 2, 2015
9.6K
11:03Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
Published on: February 10, 2020
7.7K
